Merck racks up another NICE recommendation for Keytruda

NICE

25 November 2020 - That makes it number 12.

Pembrolizumab is recommended as an option for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a combined positive score of 1 or more. 

This is only if:

  • Pembrolizumab is given as a monotherapy
  • Pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and
  • Merck provides pembrolizumab according to the commercial arrangement.

Read NICE final technology guidance for pembrolizumab

Michael Wonder

Posted by:

Michael Wonder